Verona Pharma COPD Treatment 2023 Investor Presentation

Verona Pharma presents ensifentrine, an investigational first-in-class dual PDE3/PDE4 inhibitor under FDA review for maintenance treatment of COPD. The presentation highlights a ~$10B US market opportunity, positive Phase 3 data, and the potential for broad adoption among pulmonologists, with an FDA decision date of June 26, 2024.